OABI OmniAb, Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in […] | ||
 Why Eli Lilly (LLY) Stock Is Up Today Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiring rights to a preclinical Alzheimer's drug and entering a collaboration for an ion channel program. | ||
 Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals Eli Lilly (NYSE: LLY) announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer. The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline. The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients. These deals expand Eli Lilly's external R&D partnerships... | ||
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook Licensing activity strengthens the biotech's balance sheet. | ||
Top Midday Gainers OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery progra | ||
 OmniAb lifts 2026 cash outlook following licensing momentum OmniAb, Inc. (NASDAQ:OABI) has increased its financial guidance for 2026 after recent technology licensing and business development activity strengthened its expected year-end cash position. | ||
 OmniAb (OABI) Q2 2026 Earnings Call Transcript Clinical programs advance as OmniAb raises full-year revenue guidance to $32M-$36M. | ||
 OmniAb Q2 Earnings Call Highlights OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook. Revenue for the second quarter totaled $13.4 million, compared with $3.9 million | ||
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... OmniAb raises full-year guidance to $32M-$36M, driven by milestone achievements and growing partner momentum. | ||
 OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +54.55% and +149.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||